Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual General Meeting of Shareholders for Theravance Biopharma, Inc., held on June 12, 2026. The company is incorporated in the Cayman Islands and its ordinary shares trade on the NASDAQ Global Market under the symbol TBPH.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders holding 47,059,878 ordinary shares, representing 91.4% of the total shares outstanding, were present in person or by proxy, constituting a quorum. The following matters were voted upon:
- Proposal One (Election of Directors): All six nominees were elected to serve until the 2027 Annual General Meeting.
- Laurie Smaldone Alsup: 42,725,649 For
- Susannah Gray: 42,231,530 For
- Dean J. Mitchell: 42,557,257 For
- Donal O'Connor: 42,535,463 For
- Deepika R. Pakianathan: 41,936,019 For
- Rick E Winningham: 42,474,538 For
- Proposal Two (Ratification of Auditors): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with 46,471,340 votes For.
- Proposal Three (Executive Compensation): A non-binding advisory resolution regarding the compensation of named executive officers was approved with 42,631,324 votes For.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. Detailed descriptions of the proposals are referenced as being available in the Definitive Proxy Statement filed on April 28, 2026.
Key Facts for Investor Verification
- Verify the full text of the Definitive Proxy Statement filed on April 28, 2026, for detailed rationale behind the director nominees and executive compensation.
- Confirm the specific terms of the engagement with Ernst & Young LLP for the 2026 fiscal year.
- Note that 4,156,175 broker non-votes were recorded for the director elections and executive compensation proposal, indicating shares held by brokers where no voting instruction was received.